Abstract
A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Protein & Peptide Letters
Title:In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms
Volume: 21 Issue: 4
Author(s): Nina Bionda, Irena Pastar, Stephen C. Davis and Predrag Cudic
Affiliation:
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Abstract: A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Export Options
About this article
Cite this article as:
Bionda Nina, Pastar Irena, Davis C. Stephen and Cudic Predrag, In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms, Protein & Peptide Letters 2014; 21 (4) . https://dx.doi.org/10.2174/09298665113206660101
DOI https://dx.doi.org/10.2174/09298665113206660101 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Characterization of a Bacteriophage-Derived Murein Peptidase for Elimination of Antibiotic-Resistant Staphylococcus aureus
Current Protein & Peptide Science In Vitro Synergistic Action of Certain Combinations of Gentamicin and Essential Oils
Current Medicinal Chemistry Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Current Respiratory Medicine Reviews The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology Editorial (Thematic Issue: Searching a New Antibiotic Prototype: Snake Venoms)
Mini-Reviews in Organic Chemistry Current and Future Approaches to the Prevention and Treatment of Staphylococcal Medical Device-Related Infections
Current Pharmaceutical Design Aminoglycoside Nephrotoxicity
Current Drug Targets - Infectious Disorders The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Antimicrobial Precious-Metal Nanoparticles and their Use in Novel Materials
Recent Patents on Food, Nutrition & Agriculture Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Chest Pain in Children
Current Pediatric Reviews New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Research Progress in Live Attenuated Brucella Vaccine Development
Current Pharmaceutical Biotechnology Mechanisms of Drug Hypersensitivity Reactions and the Skin
Recent Patents on Inflammation & Allergy Drug Discovery